Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abandonment, AbbVie, academic, acetate, ACR, adalimumab, African, alfa, AMPLE, Amylin, amylinomimetic, analog, andAbilify, andAtripla, andBydureon, andByetta, andForxiga, andIxempra, andKombiglyze, andKomboglyze, andNulojix, andOvcon, andPlavix, andSustiva, andSymlin, andTruvada, Appellate, Appraisal, approvedErbitux, approvedForxiga, approvedSprycel, asAbilify, asKombiglyze, asunaprevir, background, basiliximab, BBB, begun, Benckiser, borne, bothKombiglyze, Bribery, bulkErbitux, buying, Bydureon, Byetta, cancelled, capture, certainAbilify, CertainAtripla, chamber, closer, Cobicstat, comarketIscover, combiningSustiva, commercializeAbilify, commercializeAtripla, commercializeOnglyza, commercializingAtripla, compromise, concerningPlavix, containingReyataz, copromoteAbilify, copromotedPlavix, copromoteOnglyza, copromotesSprycel, costimulation, cotransporter, coveringBaraclude, coveringSprycel, coveringSustiva, CRL, currentAbilify, DAA, dedicated, deep, deflation, dexamethasone, digital, divestAbilify, Elicker, evolution, Excellence, exenatide, expenseOnglyza, FCPA, field, finishesKombiglyze, finishOnglyza, forAbilify, forAtripla, foravalide, forAvapro, forBaraclude, forBydureon, forByetta, forErbitux, forForxiga, forKombiglyze, forOnglyza, forOnglyzaandForxiga, forPlavix, forRecothrom, forReyataz, forSprycel, forSustiva, Forxiga, forYervoy, fromRecothrom, genotype, gradual, Hakko, hypertriglyceridemia, impeded, inaccurate, includesSustiva, includingGleevec, induction, inErbitux, inherited, inPlavix, Insignificant, Instructor, involvingByetta, KHK, Kirin, Kyowa, League, lenalidomide, leptine, leucovorin, lipodystrophy, Louisiana, lowerPlavix, LP, LTE, macroeconomic, malware, manufactureOnglyza, manufactureOrencia, marketSustiva, Master, matrix, mealtime, metreleptin, MINE, missed, Mississippi, Moed, mofetil, multidistrict, NAV, newer, NICE, nivolumab, NKT, nonrenewal, nonvalvular, notification, nucleoside, null, NVAF, ofAbilify, ofAtripla, ofAvalide, ofByetta, ofErbitux, ofForxiga, ofNulojix, ofOnglyza, ofOrencia, ofOrenciain, ofPlavix, ofRecothrom, ofSprycel, ofSustiva, ofSymlin, ofTruvada, ofYervoy, onOnglyza, opted, orAbilify, ORR, ourAbilify, ourPlavix, ourSustiva, Panel, payer, peak, peginterferon, pen, pendingPlavix, Portuguese, pose, PPG, pramlintide, pretrial, promoteReyataz, pulmonary, questionable, Racketeer, RBL, Reckitt, recommendedYervoy, regardingRecothrom, regiment, reinstatement, repaid, resubmit, revert, Rheumatism, ribavarin, rollover, SA, Samuel, satisfactorily, SC, sellAbilify, sellOnglyza, Serono, seropositive, showedForxiga, sitagliptin, sitigliptin, soldIscover, soldPlavix, Spanish, Stanford, strained, stratified, string, symptomatic, takingForxiga, Taxpayer, thatOrencia, theabilify, theAvalide, theOrencia, thePlavix, therapyAtripla, theRecothrom, thereof, thesustiva, thrombin, toAbilify, toAtripla, toByetta, toErbitux, toOnglyza, toPlavix, toRecothrom, toSprycel, toSustiva, toSymlin, toYervoy, tracked, tradenameIscover, tradenamePlavix, Triple, underperform, unexpected, unpredictable, unsecured, unvested, uptake, usingByetta, usingPlavix, usingReglan, Valeant, vast, vein, vinorelbine, vulnerable, whenAbilify, whereAbilify, withAbilify, withErbitux, withNorvir, withPlavix, withYervoy, wrongful
Removed:
ABILFY, accrue, adjust, Africa, aggregated, Alder, aspirin, assumption, attractive, autoimmune, automatically, AVALIDE, AVAPRO, avoidance, AWP, balanced, began, behavior, blended, borrowed, calculating, calibration, capitalize, Celentano, Celldex, center, characterized, charged, closure, Cobalt, conceding, consented, consolidate, convert, converted, converting, core, counterclaim, creating, crediting, curtailment, decade, declaratory, decompensated, deducting, DELESTROGEN, disrupt, distinct, divest, Dr, East, eliminate, elimination, enoxaparin, Estradiol, exert, FGF, forinter, gained, Genmab, GLEEVEC, HCl, holder, hydrogen, IIa, IIIb, improved, improving, inactive, infiltration, inflammation, instability, instance, instituted, ISCOVER, IXEMPRA, matching, maturing, middle, Minister, Modernization, modified, negotiate, Nissan, nominal, nomination, NORVIR, occurrence, optimize, orderly, Ottawa, outpatient, output, outsourced, OVCON, partnered, PBM, PDUFA, Pharma, Pharmastar, plaintiff, power, precluding, predominately, prepare, preventing, prospective, protecting, PTO, published, pursued, recovered, Reddy, reexamination, refractory, rejected, relationship, released, reliably, remeasured, repay, replacement, representative, resistant, retiree, role, segregated, select, separation, shutdown, size, solid, stability, standardization, statistically, step, strong, sulfonylurea, syndicated, tailoring, tender, thromboembolism, tradename, trailing, transplantation, TRUVADA, undergo, underwriting, user, utility, vacated, vascular, VEGF, vested, vote, Watson, wealth, weighting, yielded
Filing tables
Filing exhibits
- 10-K Annual report
- 10 EX-10.P
- 10 EX-10.Q
- 10 EX-10.R
- 10 EX-10.S
- 10 EX-10.T
- 10 EX-10.U
- 10 EX-10.V
- 10 EX-10.W
- 10 EX-10.X
- 10 EX-10.Y
- 10 EX-10.Z
- 10 EX-10.AA
- 10 EX-10.EE
- 10 EX-10.OO
- 10 EX-10.PP
- 10 EX-10.QQ
- 10 EX-10.RR
- 10 EX-10.WW
- 10 EX-10.XX
- 12 EX-12
- 21 EX-21
- 23 EX-23
- 31 EX-31.A
- 31 EX-31.B
- 32 EX-32.A
- 32 EX-32.B
Related press release
BMY similar filings
Filing view
External links
EXHIBIT 12.
Computation of Earnings to Fixed Charges
Ratio of Earnings to Fixed Charges:
Year Ended December 31, | ||||||||||||||||||||
Dollars in Millions | 2012 | 2011 | 2010 | 2009 | 2008 | |||||||||||||||
Earnings | ||||||||||||||||||||
Earnings from continuing operations before income taxes | $ | 2,340 | $ | 6,981 | $ | 6,071 | $ | 5,602 | $ | 4,776 | ||||||||||
Less: | ||||||||||||||||||||
Noncontrolling interest in pre-tax income of subsidiaries that have not incurred fixed charges | 844 | 2,323 | 2,074 | 1,717 | 1,444 | |||||||||||||||
Equity in net income of affiliates | 183 | 281 | 313 | 550 | 617 | |||||||||||||||
Capitalized interest | — | — | 8 | 13 | 21 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Income adjusted for equity income | 1,313 | 4,377 | 3,676 | 3,322 | 2,694 | |||||||||||||||
Add: | ||||||||||||||||||||
Fixed charges | 227 | 190 | 201 | 242 | 387 | |||||||||||||||
Distributed income of equity investments | 229 | 283 | 313 | 550 | 590 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Total Earnings | $ | 1,769 | $ | 4,850 | $ | 4,190 | $ | 4,114 | $ | 3,671 | ||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Fixed Charges | ||||||||||||||||||||
Interest expense | $ | 182 | $ | 145 | 145 | $ | 184 | $ | 310 | |||||||||||
Capitalized interest | — | — | 8 | 13 | 21 | |||||||||||||||
One-third of rental expense(1) | 45 | 45 | 48 | 45 | 56 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Total Fixed Charges | $ | 227 | $ | 190 | $ | 201 | $ | 242 | $ | 387 | ||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Ratio of Earnings to Fixed Charges | 7.79 | 25.53 | 20.85 | 17.00 | 9.49 |
(1) | Rents included in the computation consist of one-third of rental expense which the Company believes to be a reasonable estimate of an interest factor in its leases. |
E-12-1